ARCHIVES

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

This article is from The Cancer Letter archive.

Vol. 36 No. 8 | August 30, 2013

Download PDF Visit The Full Archive

Related Articles

Phase III Cyramza Trial Meets OS Primary Endpoint

September 26, 2014

Excitement building toward 2015 goal, NCI director says in FY07 bypass budget request. NCI seeks $5.8 billion.

December 2, 2005

NCI Raises New Questions About Duke Genomics Research, Cuts Assay From Trial

May 14, 2010

Assurances On Methods For Misconduct Reporting Required

December 1, 1989

Itri Pays Fine, Agrees Not to Serve As Company Officer for Five Years

April 25, 2014

Lymphedema Education Helps Reduce Symptoms, Study Finds

August 28, 2009